Benzydamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Benzydamine
Accession Number
DB09084
Type
Small Molecule
Groups
Approved
Description

Benzydamine (also known as Tantum Verde and branded in some countries as Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of typically topical inflammatory conditions associated with the mouth, throat, or muscoskeletal locations.

Although the indazole analogue benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but facilitate benzydamine's mechanism of action as an effective locally-acting NSAID with local anaesthetic and analgesic properties. Moreover, unlike aspirin-like NSAIDs which are acids or metabolised to acids, benzydamine is in fact a weak base.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Benzydamine hydrochlorideK2GI407R4Q132-69-4HNNIWKQLJSNAEQ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PharixiaMouthwash1.5 mgBuccalPendopharm Division Of De Pharmascience Inc1996-12-02Not applicableCanada
Sun-benz - Liq 0.15%Liquid.15 %Dental; OralSun Pharmaceutical Industries Limited1997-04-032011-07-29Canada
TantumSolution15 mgBuccalValeant Canada Lp Valeant Canada S.E.C.1993-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-benzydamine Oral RinseLiquid0.15 %BuccalApotex Corporation1998-11-09Not applicableCanada
Novo-benzydamineMouthwash; Solution1.5 mgBuccal; OralNovopharm Limited2008-06-03Not applicableCanada
Novo-benzydamine - Oral RinseLiquid; Mouthwash1.5 mgBuccal; OralNovopharm Limited1997-02-062015-10-26Canada
Nu-benzydamine Oral RinseLiquid0.15 %BuccalNu Pharm IncNot applicableNot applicableCanada
Odan-benzydamineMouthwash1.5 mgBuccalOdan Laboratories Ltd2017-08-11Not applicableCanada
PMS-benzydamineMouthwash1.5 mgBuccalPharmascience Inc1999-04-30Not applicableCanada
Ratio-benzydamineSolution0.15 %OralRatiopharm Inc Division Of Teva Canada Limited1997-03-242010-05-21Canada
Categories
UNII
4O21U048EF
CAS number
642-72-8
Weight
Average: 309.413
Monoisotopic: 309.184112373
Chemical Formula
C19H23N3O
InChI Key
CNBGNNVCVSKAQZ-UHFFFAOYSA-N
InChI
InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3
IUPAC Name
{3-[(1-benzyl-1H-indazol-3-yl)oxy]propyl}dimethylamine
SMILES
CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12

Pharmacology

Indication

Available predominantly as a liquid mouthwash, oromucosal spray, or topical cream, benzydamine is most frequently employed as a locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions.

When formulated as a mouthwash or spray, benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a naso-gastric tube, inflammatory conditions like pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy, dentistry operations and procedures, or more general conditions like sore throat, sore tongue, sore gums, mouth ulcers, or discomfort caused by dentures. [6]

When used as a topical cream, benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscolo-skeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains, strains, bruises, sore muscles, stiff joints, or even the after-effects of fractures. [7]

Structured Indications
Pharmacodynamics

Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) designed to elicit local anesthetic and analgesic effects mainly for the mouth and throat. It specifically acts on the local mechanisms of inflammation such as pain, oedema, or granuloma. Typically applied topically, the drug demonstrates anti-inflammatory activity reducing oedema as well as exudate and granuloma formation. Moreover, benzydamine exhibits analgesic properties and local anaesthetic activity if pain is caused by an inflammatory condition. Benzydamine can be absorbed into the oral mucosa and intact skin. Once absorbed in the local area of pain or inflammation, benzydamine binds selectively to local inflamed tissues, usually allowing it to act with few adverse systemic effects. On average a period of 2 to 4 hours is necessary for the substance to reach peak plasma concentration. [5]

Benzydamine can be synthesized with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give N-nitoso derivative. This is next reduced by sodium thiosulfate to give transient hydrazine. This hydrazine can then undergo spontaneous internal hydrazide formation. Treating this resultant enolate with 3-chloro-1-dimethylamkino propane ultimately yields benzydamine.

Mechanism of action

Despite being categorized as a non-steroidal anti-inflammatory drug (NSAID), benzydamine demonstrates various mechanisms of action that differ from those of traditional aspirin-like NSAIDs. In particular, benzydamine predominantly acts by inhibiting the synthesis of pro inflammatory cytokines like tumour necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) without largely affecting other pro inflammatory cytokines (ie. such as IL-6 and IL-8) or anti-inflammatory cytokines (ie. like IL-10 or IL-1 receptor antagonist). [3, 5]

Moreover, benzydamine is largely a weak inhibitor of prostaglandin synthesis as it has been shown to effectively inhibit cyclooxygenase (COX) and lipoxygenase enzyme activity only at concentrations of 1mM or greater. Considering most contemporary usages of benzydamine are topical applications that are generally not well absorbed through the skin and/or non-specialized mucosae, benzydamine does not often achieve the kind of absorption or blood concentrations necessary to cause any extraneous distant systemic effects or COX inhibition, allowing it to localize its action. [3, 5]

Additionally, it is also hypothesized that benzydamine is capable of inhibiting the oxidative burst of neutrophils and membrane stabilization. These actions are exhibited by the substance’s ability to inhibit the release of granules from neutrophils and to stabilize lysosomes. [3, 5]

Furthermore, benzydamine is capable of a local anaesthetic effect that may be related to its capability for inhibiting the release of inflammatory mediators like substance P and calcitonin gene related peptide from sensory nerve endings. Since substance P is capable of causing the release of histamine from mast cells, benzydamine’s prevention of substance P release further contributes to an anti-inflammatory effect. [3, 5]

Benzydamine also demonstrates a non-specific antibacterial activity against various bacterial strains that are resistant to broad-spectrum antibiotics such as ampicillin, chloramphenicol, and tetracycline at concentrations of about 3 mmol/L. Combinatorial use of benzydamine and other antibiotics like tetracycline and chloramphenicol are also synergistic against antibiotic resistant strains of Staphylococcus aureus and Pseudomonas aeruginosa. [3]

Absorption

Oral doses of benzydamine are well absorbed and plasma drug concentrations reach a peak fairly rapidly and then decline with a half-life of approximately 13 hours. When applied topically, although the local drug concentrations are relatively large, the systemic absorption of topically applied benzydamine is relatively low compared to oral doses. This low topical absorption contributes to a decreased potential for any systemic drug side-effects when benzydamine is administered in this way. [6]

Volume of distribution

The volume of distribution of benzydamine is 10 L [1, 3].

Protein binding

Benzydamine exhibits < 20% plasma protein binding after oral administration [6, 3].

Metabolism

Benzydamine is primarily metabolised by oxidation, dealkylation, and conjugation into hydroxy, dealkylated, and N-oxide metaboiltes [6, 3].

Route of elimination

The relatively high lipid solubility of the weak base benzydamine is thought to be associated with considerable passive resorption within the renal tubule, which suggests that only approximately 5% of benzydamine is excreted unchanged in the urine [1]. At the same time however, other studies have suggested that considerably larger amounts (50-65%) of the drug is excreted unchanged in urine [4].

While several inactive oxidized metabolites of benzydamine are excreted in urine, the benzydamine N-oxide metabolite can remain in plasma and demonstrate a half-life that is longer than the parent benzydamine compound [1].

Half life

Approximately 13 h after oral administration [6], with a terminal half life of about 7.7 h [3].

Clearance

Benzydamine demonstrateas a systemic clearance of 170 ml/min [3].

Toxicity

A possible adverse reaction associated with the use of the mouthwash or oromucosal spray formulations of benzymadine is potential numbness and/or stinging in the mouth and/or throat [5, 6].

Some possible adverse reactions that tend to be associated more with topical cream formulations of benzymadine include increased sensitivity to sunlight, and localized itching, skin rash, redness, or swelling [7].

The prescribing information for all formulations of benzymadine however, warn against the possibility of severe allergic reaction (anaphylaxis) associated with swelling of the throat and mouth, difficulty in swallowing, speaking, and breathing, or wheezing [5, 6, 7].

As benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it is necessary to determine if a patient is allergic to NSAIDs before considering its use [5, 6, 7].

Intoxication is expected as a consequence of accidental ingestion of large quantities of benzydamine (over 300 mg ingestion). Other symptoms associated with overdose of ingested benzydamine include gastrointestinal and central nervous system symptoms like nausea, vomiting, abdominal pain, oesophageal irritation, dizziness, hallucinations, agitation, anxiety, and irritability [6].

The official prescribing information for benzydamine generally suggest that benzydamine mouthwashes and sprays should not be used in pregnancy [6, 7] . Similarly, the official prescribing information for benzydamine also generally suggest that benzydamine mouthwashes and sprays should not be used during lactation unless considered essential by a physician [6, 7].

The prescribing information for topical cream formulations of benzydamine note that benzydamine cream should not be used in pregnancy or lactation unless considered necessary by the physician [5].

Overall, non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeated toxicity, genotoxicity, cardiogenic potential, and toxicity to reproduction [5]. Additionally, there is no evidence of teratogenic effects in animal studies [6].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Benzydamine.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Benzydamine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Benzydamine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Benzydamine is combined with 5-androstenedione.Experimental, Illicit
AbciximabBenzydamine may increase the anticoagulant activities of Abciximab.Approved
AcebutololBenzydamine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Benzydamine.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Benzydamine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolBenzydamine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Benzydamine.Approved, Vet Approved
AclarubicinBenzydamine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Benzydamine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Benzydamine.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Aldosterone.Experimental, Investigational
AldoxorubicinBenzydamine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Benzydamine is combined with Alendronic acid.Approved
AliskirenBenzydamine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Benzydamine.Experimental
AlprenololBenzydamine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Benzydamine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Amcinonide.Approved
AmikacinBenzydamine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideBenzydamine may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinBenzydamine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodBenzydamine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Benzydamine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Benzydamine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Benzydamine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Benzydamine.Investigational
AnnamycinBenzydamine may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Benzydamine.Approved, Investigational
Antithrombin III humanBenzydamine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanBenzydamine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Benzydamine.Investigational
ApramycinBenzydamine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Benzydamine.Approved, Investigational
ArbekacinBenzydamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinBenzydamine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBenzydamine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBenzydamine may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Atamestane.Investigational
AtenololBenzydamine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Benzydamine.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Benzydamine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Benzydamine is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benzydamine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Benzydamine.Investigational
BalsalazideBenzydamine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminBenzydamine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololBenzydamine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinBenzydamine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Benzydamine.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Benzydamine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Benzydamine.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Benzydamine.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Benzydamine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Betamethasone.Approved, Vet Approved
BetaxololBenzydamine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Benzydamine.Approved, Investigational
BevantololBenzydamine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Benzydamine.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Benzydamine.Approved, Investigational
BisoprololBenzydamine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBenzydamine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololBenzydamine may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Benzydamine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Benzydamine.Investigational
BucindololBenzydamine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Benzydamine.Approved, Experimental
BufuralolBenzydamine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Benzydamine.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Benzydamine.Approved
BupranololBenzydamine may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Benzydamine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benzydamine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Benzydamine.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Benzydamine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Benzydamine.Approved, Vet Approved, Withdrawn
CarteololBenzydamine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBenzydamine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Benzydamine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Benzydamine is combined with Celecoxib.Approved, Investigational
CeliprololBenzydamine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinBenzydamine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Benzydamine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benzydamine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Benzydamine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Benzydamine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Cilazapril.Approved
CinoxacinBenzydamine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidBenzydamine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Benzydamine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Benzydamine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Benzydamine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Benzydamine.Vet Approved
CloranololBenzydamine may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Benzydamine.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Benzydamine.Experimental
CyclosporineBenzydamine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateBenzydamine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinBenzydamine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBenzydamine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanBenzydamine may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinBenzydamine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Benzydamine is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Benzydamine is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Delapril.Experimental
DesirudinBenzydamine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Benzydamine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benzydamine.Approved, Investigational
DextranBenzydamine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Benzydamine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Benzydamine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Benzydamine may increase the anticoagulant activities of Dextran 75.Approved
DibekacinBenzydamine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Benzydamine is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Benzydamine.Approved, Vet Approved
DicoumarolBenzydamine may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Benzydamine.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Benzydamine.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Benzydamine.Approved
DihydrostreptomycinBenzydamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Benzydamine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Benzydamine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Benzydamine.Approved
DoxorubicinBenzydamine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneBenzydamine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Benzydamine.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Benzydamine.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Benzydamine.Investigational
Edetic AcidBenzydamine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBenzydamine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Benzydamine is combined with Enalaprilat.Approved
EnoxacinBenzydamine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinBenzydamine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Benzydamine.Experimental
EpanololBenzydamine may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Benzydamine.Approved
EpirubicinBenzydamine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Benzydamine.Experimental
EplerenoneBenzydamine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Benzydamine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benzydamine.Approved
EquileninThe risk or severity of adverse effects can be increased when Benzydamine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Benzydamine is combined with Equilin.Approved
EsmololBenzydamine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benzydamine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Benzydamine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Benzydamine.Experimental
Ethyl biscoumacetateBenzydamine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Benzydamine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Benzydamine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Benzydamine.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Benzydamine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Benzydamine.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Benzydamine.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Benzydamine.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Benzydamine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Benzydamine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Benzydamine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Benzydamine.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Benzydamine.Experimental
Ferulic acidBenzydamine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Benzydamine.Approved, Investigational
FleroxacinBenzydamine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Benzydamine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fludrocortisone.Approved, Investigational
FluindioneBenzydamine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineBenzydamine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Benzydamine.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Benzydamine.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Benzydamine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Benzydamine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Benzydamine.Approved, Nutraceutical, Vet Approved
FondaparinuxBenzydamine may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumBenzydamine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Benzydamine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fosinopril.Approved
FramycetinBenzydamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Benzydamine.Approved, Vet Approved
GabexateBenzydamine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBenzydamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBenzydamine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Benzydamine.Approved, Withdrawn
GemifloxacinBenzydamine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBenzydamine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinBenzydamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABenzydamine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Benzydamine may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinBenzydamine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Benzydamine.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Benzydamine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Benzydamine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Benzydamine is combined with HE3286.Investigational
HeparinBenzydamine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Benzydamine.Investigational
HydralazineBenzydamine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benzydamine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Benzydamine.Approved, Investigational
Hygromycin BBenzydamine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Benzydamine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Benzydamine.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Benzydamine.Approved, Investigational
IdarubicinBenzydamine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxBenzydamine may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Benzydamine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Benzydamine.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Benzydamine.Approved
IndenololBenzydamine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Benzydamine.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Benzydamine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Benzydamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benzydamine.Approved, Investigational
IsepamicinBenzydamine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Benzydamine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Benzydamine is combined with Istaroxime.Investigational
KanamycinBenzydamine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Benzydamine.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Benzydamine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Benzydamine.Approved
LabetalolBenzydamine may decrease the antihypertensive activities of Labetalol.Approved
LandiololBenzydamine may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Benzydamine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Benzydamine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Benzydamine.Approved, Investigational
LepirudinBenzydamine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanBenzydamine may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololBenzydamine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBenzydamine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Benzydamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Benzydamine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Benzydamine.Approved
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Benzydamine.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Benzydamine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Benzydamine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Benzydamine is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Benzydamine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Benzydamine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Benzydamine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Benzydamine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benzydamine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Benzydamine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Benzydamine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benzydamine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Benzydamine.Approved
MelagatranBenzydamine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Benzydamine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Benzydamine.Approved, Vet Approved
MepindololBenzydamine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineBenzydamine may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Benzydamine.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Benzydamine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benzydamine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololBenzydamine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Benzydamine.Approved
MetoprololBenzydamine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideBenzydamine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinBenzydamine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Benzydamine.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Benzydamine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Benzydamine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Benzydamine.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Benzydamine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Benzydamine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benzydamine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Nabumetone.Approved
NadololBenzydamine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinBenzydamine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatBenzydamine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Benzydamine.Approved
Nalidixic AcidBenzydamine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Benzydamine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Benzydamine is combined with NCX 1022.Investigational
NeamineBenzydamine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololBenzydamine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinBenzydamine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinBenzydamine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Benzydamine.Approved, Investigational
NetilmicinBenzydamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Benzydamine.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Benzydamine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benzydamine.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Benzydamine.Investigational
NorfloxacinBenzydamine may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benzydamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benzydamine.Approved
OlsalazineBenzydamine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Benzydamine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Benzydamine is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Benzydamine.Vet Approved
OtamixabanBenzydamine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Benzydamine.Approved
Oxolinic acidBenzydamine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololBenzydamine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benzydamine.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Benzydamine is combined with Parecoxib.Approved
ParomomycinBenzydamine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Benzydamine.Approved, Investigational
PazufloxacinBenzydamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBenzydamine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBenzydamine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateBenzydamine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateBenzydamine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Perindopril.Approved
PhenindioneBenzydamine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonBenzydamine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Benzydamine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benzydamine.Approved, Investigational
PindololBenzydamine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidBenzydamine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinBenzydamine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Benzydamine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Benzydamine.Approved, Investigational
Piromidic acidBenzydamine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Benzydamine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Benzydamine.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Benzydamine is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorBenzydamine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinBenzydamine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinBenzydamine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Benzydamine.Approved
PractololBenzydamine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Benzydamine.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Benzydamine.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Benzydamine can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Benzydamine.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Benzydamine.Approved, Investigational
PropranololBenzydamine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Benzydamine.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Benzydamine.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Benzydamine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Benzydamine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Benzydamine.Vet Approved
Protein CBenzydamine may increase the anticoagulant activities of Protein C.Approved
Protein S humanBenzydamine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBenzydamine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBenzydamine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Benzydamine.Investigational
PuromycinBenzydamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Benzydamine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Benzydamine.Approved, Experimental, Investigational
ReviparinBenzydamine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinBenzydamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Risedronate.Approved, Investigational
RivaroxabanBenzydamine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Benzydamine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinBenzydamine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinBenzydamine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinBenzydamine may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Benzydamine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Benzydamine.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Benzydamine.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Benzydamine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benzydamine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Benzydamine.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Benzydamine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Benzydamine.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Benzydamine.Investigational
SisomicinBenzydamine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinBenzydamine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Benzydamine.Approved
SotalolBenzydamine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CBenzydamine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinBenzydamine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinBenzydamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Spirapril.Approved
SpironolactoneBenzydamine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Benzydamine.Investigational
StreptomycinBenzydamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinBenzydamine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Benzydamine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Benzydamine.Approved, Investigational
SulodexideBenzydamine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Benzydamine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Benzydamine.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Benzydamine.Experimental
TacrolimusBenzydamine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Benzydamine.Approved
TalinololBenzydamine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Benzydamine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Benzydamine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Benzydamine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Benzydamine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benzydamine.Approved, Investigational
TemafloxacinBenzydamine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Benzydamine.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Benzydamine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Benzydamine.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Benzydamine.Approved
TertatololBenzydamine may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Benzydamine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Benzydamine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololBenzydamine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Benzydamine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Benzydamine is combined with Tixocortol.Approved, Withdrawn
TobramycinBenzydamine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benzydamine.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Benzydamine.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Benzydamine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Benzydamine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Benzydamine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Benzydamine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Benzydamine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBenzydamine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Benzydamine.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Benzydamine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Benzydamine.Investigational
TrovafloxacinBenzydamine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinBenzydamine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Benzydamine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Benzydamine.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Benzydamine is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinBenzydamine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Benzydamine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Benzydamine.Approved
WarfarinBenzydamine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBenzydamine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benzydamine.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Benzydamine.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Benzydamine is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Benzydamine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Benzydamine.Withdrawn
Zoptarelin doxorubicinBenzydamine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinBenzydamine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Baldock GA, Brodie RR, Chasseaud LF, Taylor T, Walmsley LM, Catanese B: Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects. Biopharm Drug Dispos. 1991 Oct;12(7):481-92. [PubMed:1932611]
  2. Silvestrini B, Barcellona PS, Garau A, Catanese B: Toxicology of benzydamine. Toxicol Appl Pharmacol. 1967 Jan;10(1):148-59. [PubMed:6031923]
  3. Quane PA, Graham GG, Ziegler JB: Pharmacology of benzydamine. Inflammopharmacology. 1998;6(2):95-107. doi: 10.1007/s10787-998-0026-0. [PubMed:17694367]
  4. Catanese B, Grasso A, Silverstrini B: Studies on the absorption and elimination of benzydamine in the mouse, rat, dog, and man. Arzneimittelforschung. 1966 Oct;16(10):1354-7. [PubMed:6014929]
  5. Electronic Medicines Compedium Difflam (Benzydamine Hydrochloride) Spray Monograph [Link]
  6. Electronic Medicines Compedium Benzydamine Hydrochloride 0.15% w/v Mouthwash Monograph [Link]
  7. Electronic Medicines Compedium Difflam (Benzydamine Hydrochloride) 3% Cream Monograph [Link]
External Links
PubChem Compound
12555
PubChem Substance
310265011
ChemSpider
12036
BindingDB
50095471
ChEBI
94563
ChEMBL
CHEMBL12610
Wikipedia
Benzydamine
ATC Codes
M01AX07 — BenzydamineM02AA05 — BenzydamineA01AD02 — BenzydamineG02CC03 — Benzydamine
AHFS Codes
  • 52:28.00 — Mouthwashes and Gargles
  • 52:08.20 — Nonsteroidal Anti-inflammatory Agents
MSDS
Download (343 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedSupportive CareHead and Neck Carcinoma / Mucositis1
3Unknown StatusPreventionFor Intervention1
4CompletedOtherIntubation Complications1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidBuccal0.15 %
Mouthwash; solutionBuccal; Oral1.5 mg
Liquid; mouthwashBuccal; Oral1.5 mg
MouthwashBuccal1.5 mg
SolutionOral0.15 %
LiquidDental; Oral.15 %
SolutionBuccal15 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)320°FMSDS
water solubilityMiscibleMSDS
Predicted Properties
PropertyValueSource
Water Solubility0.0491 mg/mLALOGPS
logP3.78ALOGPS
logP3.66ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)9.26ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area30.29 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity105.56 m3·mol-1ChemAxon
Polarizability35.62 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrazoles
Sub Class
Indazoles
Direct Parent
Indazoles
Alternative Parents
Alkyl aryl ethers / Benzene and substituted derivatives / Pyrazoles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Benzopyrazole / Indazole / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid / Azole / Pyrazole / Heteroaromatic compound / Tertiary amine / Tertiary aliphatic amine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on September 15, 2015 13:55 / Updated on April 17, 2018 01:10